Abu Dhabi’s Stem Cell Center successfully treats hematomas

Last updated on February 16th, 2021 at 07:17 am

The Abu Dhabi Stem Cells Centre (ADSCC), which introduced the Abu Dhabi Bone Marrow Transplant program (AD-BMT) in July 2020, exhibited exemplary results as it successfully teated patients suffered from leukemia. It marked a pathbreaking success, given the short span of time since the program was launched. Many believed that the success of the treatment vouched for the high standards of health care provided by the UAE.

The success story of six patients, who got treated of hematomas, using hematopoietic stem cell transplantation, placed Emirates among some of the finest medical facilities in the world. The AD-BMT program, which started taking cases from early August 2020, treated patients with different types of blood malignancies including Multiple Myeloma, Plasma Cell Leukemia, Large Diffuse B-Cell Lymphoma and Hodgkin Lymphoma. The treatment which generally varied for each patient, lasted from about 19 days to up to one month.

The programme’s successful medical record encouraged ADSCC to apply for international accreditation. The ADSCC has been working towards adopting a more environmentally conscious approach by coupling technology with sustainable and eco-friendly practices. It also committed to embrace more innovative measures and translational research. The programme’a futuristic approach sets a high mark, which the authorities believe would help in its expansion plan, eventually offering other procedures and treatments.

Related Posts

• Abu Dhabi’s Stem Cell Center successfully treats its first Emirati patient through bone marrow transplant
• How Dubai Is Desperate To Get Back To Tourism Normal
• UAE Hope Probe successfully enters Mars orbit
• What is Vasculitis that hit Ashton Kutcher?

The ADSCC reported that the AD-BMT program has been continuously taking more cases and treating patients while working towards its expansion so that it can treat more than one patient simultaneously. Its goal for the near future is to provide treatment for not only hematological issues but also other disorders including autoimmune diseases and primary immune deficiencies.